Clinical Trial Update: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine [Phase 3]

View source ↗

Summary

A Phase 3 pediatric study evaluating lasmiditan for migraine in children aged 6 to 17 has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Lasmiditan (Lasmiditan)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 3 | Status: TERMINATED